KR860001471B1
(ko)
|
1980-04-03 |
1986-09-26 |
비오겐 엔. 브이 |
인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
|
EP0188479B1
(fr)
*
|
1984-07-06 |
1991-09-11 |
Sandoz Ag |
Production et purification de lymphokine
|
JPS61227526A
(ja)
*
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
UA29377C2
(uk)
*
|
1984-09-19 |
2000-11-15 |
Новартіс Аг |
Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
|
AU608741B2
(en)
*
|
1984-11-20 |
1991-04-18 |
Schering Biotech Corporation |
cDNA clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
DE3681551D1
(de)
*
|
1985-09-30 |
1991-10-24 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granulozyten-colony stimulierender faktor.
|
JPH0618778B2
(ja)
*
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
DE3545568A1
(de)
*
|
1985-12-21 |
1987-07-16 |
Hoechst Ag |
Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
|
US5298603A
(en)
*
|
1985-12-21 |
1994-03-29 |
Hoechst Aktiengesellschaft |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
|
EP0232707A1
(fr)
*
|
1986-01-09 |
1987-08-19 |
Ajinomoto Co., Inc. |
Facteur humain d'augmentation de la croissance de cellules hématopoiétiques
|
US5106733A
(en)
*
|
1987-06-25 |
1992-04-21 |
Immunex Corporation |
Bovine granulocyte-macrophage colony stimulating factor
|
EP0413721A4
(en)
*
|
1988-04-21 |
1991-11-13 |
Medvet Science Pty. Ltd. |
Human gm-csf variants
|
SG59954A1
(en)
*
|
1989-08-11 |
1999-02-22 |
Amrad Corp Ltd |
Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
|
EP0711829A3
(fr)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Vecteurs composés d'alphavirus recombinants
|
EP0791061A4
(fr)
*
|
1994-03-04 |
1998-07-15 |
Ludwig Inst Cancer Res |
Animaux a rupture genique ciblee
|
EP1997900A3
(fr)
|
1996-04-05 |
2010-10-06 |
Novartis Vaccines and Diagnostics, Inc. |
Vecteurs à base d'alpha virus recombinants avec inhibition réduite de synthèse macromoléculaire cellulaire
|
WO1998012332A1
(fr)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions et procedes de traitement de maladies intracellulaires
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
AU751898B2
(en)
*
|
1997-07-14 |
2002-08-29 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
EP1019082B2
(fr)
|
1997-10-02 |
2008-06-04 |
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. |
Utiliastion d'un facteur des colonies (csf) pour augmenter la croissance collaterale des arteres collaterales et/ou d'autres arteres a partir de connexions arteriolaires preexistantes
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
EP1980617A1
(fr)
|
1998-12-31 |
2008-10-15 |
Novartis Vaccines and Diagnostics, Inc. |
Expression améliorée de polypeptides HIV et production de particules de type virus
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
ATE446767T1
(de)
*
|
1999-02-12 |
2009-11-15 |
Univ Washington |
Gm-csf zur behandlung von morbus crohn
|
US6911204B2
(en)
*
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
US20030012782A1
(en)
*
|
2000-08-11 |
2003-01-16 |
Gold Daniel P. |
Method and composition for altering a T cell mediated pathology
|
CA2452119C
(fr)
|
2001-07-05 |
2013-10-15 |
Chiron Corporation |
Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
|
CA2634992C
(fr)
|
2001-07-05 |
2012-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
|
US7714113B2
(en)
|
2002-02-13 |
2010-05-11 |
Ludwig Institute For Cancer Research |
Fusion proteins of humanized g250 specific antibodies and uses thereof
|
ES2627445T3
(es)
|
2002-05-01 |
2017-07-28 |
Miltenyi Biotec Technology, Inc. |
Partículas de vector de lentivirus resistentes a la inactivación por el complemento
|
GB0210741D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Medical Res Council |
Methods of therapy
|
GB0224415D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Medical Res Council |
Compositions
|
AU2004269320B2
(en)
|
2003-06-20 |
2009-12-24 |
Protein Sciences Corporation |
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
|
WO2006050394A2
(fr)
|
2004-11-01 |
2006-05-11 |
Novartis Vaccines And Diagnostics Inc. |
Approches combinatoires destinees a produire des reponses immunitaires
|
GB0524103D0
(en)
*
|
2005-11-26 |
2006-01-04 |
Medical Res Council |
Healing
|
CA2641169C
(fr)
|
2006-02-08 |
2017-05-02 |
Morphotek, Inc. |
Peptides antigeniques du facteur de stimulation de colonie de granulocytes (gm-csf) et anticorps au gm-csf
|
WO2007137300A2
(fr)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Cellules dendritiques modifiées à survie et immunogénicité améliorées et compositions et procédés connexes
|
EP2498795B1
(fr)
|
2009-10-12 |
2016-12-07 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Granulysine dans l'immunothérapie
|
WO2012093258A2
(fr)
|
2011-01-05 |
2012-07-12 |
Imperial Innovations Limited |
Traitement et criblage
|
EP2870238A4
(fr)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
Compositions et procédés associés à des vaccins viraux
|
EP3344290A4
(fr)
|
2015-08-31 |
2019-02-27 |
Technovax, Inc. |
Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
|
EP3805376A1
(fr)
|
2016-01-08 |
2021-04-14 |
Replimune Limited |
Virus modifié
|
US10538786B2
(en)
|
2016-04-13 |
2020-01-21 |
Janssen Pharmaceuticals, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
AU2017347725B2
(en)
|
2016-10-17 |
2024-01-04 |
Janssen Pharmaceuticals, Inc. |
Recombinant virus replicon systems and uses thereof
|
MX2019006467A
(es)
|
2016-12-05 |
2019-12-09 |
Janssen Pharmaceuticals Inc Star |
Composiciones y métodos para mejorar la expresión génica.
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
KR20200111729A
(ko)
|
2018-01-19 |
2020-09-29 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
|